Last reviewed · How we verify
NCT06030648
MT2022-01: MSCs for ALD
Phase 1 trial testing Mesenchymal stem cells (IV-MSC) in Cerebral Adrenoleukodystrophy in 10 participants. Suspended.
1 May 2026
Quick facts
| Lead sponsor | Masonic Cancer Center, University of Minnesota |
|---|---|
| Phase | Phase 1 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 28 August 2023 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Mesenchymal stem cells (IV-MSC) — full drug profile →
Conditions studied
- Cerebral Adrenoleukodystrophy — all drugs for Cerebral Adrenoleukodystrophy →
Sponsor
Masonic Cancer Center, University of Minnesota
Who can join
3 and older, any sex, with Cerebral Adrenoleukodystrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-institution study to evaluate the use of intravenously administered allogeneic, 3rd party mesenchymal stem cells (IV-MSC) in patients with active, cerebral adrenoleukodystrophy (CALD), as a bridge to hematopoietic stem cell transplant or gene therapy, or in patients who are too advanced for gene therapy or HSCT. The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies.
Wang J, Zhang M, Wang H. · · 2024 · cited 13× · PMID 39144566 · DOI 10.1021/acsptsci.4c00284 -
Stem cell and gene therapies for leukodystrophies.
Lin W, Zhang M, Zheng S, Lian Q. · · 2025 · cited 1× · PMID 40836959 · DOI 10.1016/j.omtm.2025.101527
Verify or expand the search:
- PubMed search for NCT06030648
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Masonic Cancer Center, University of Minnesota trials
Trials by the same sponsor.
- NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies · NA · not yet recruiting
- NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
- NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
- NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
- NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06030648 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
- Last refreshed: 30 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06030648.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing